Evidence map›Paper›PMID 41547653›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026

Pharmacological characterization and neuroprotective efficacy of ZHB103, a novel long-acting rhKLK1.

Dan Xu, Chenyang Jiang, Chennan Ge, Tao Zhang, Jun Wang, He Wang, Yu Zhuang, Zhen Xu, Na Ding, Bruce Yong Ma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dan XuZonHon Biopharma Institute, Inc., Changzhou, Jiangsu, China; Jiangsu Engineering Research Center for Precision Biomedicines, Changzhou, Jiangsu, China.
Chenyang JiangZonHon Biopharma Institute, Inc., Changzhou, Jiangsu, China; Jiangsu Engineering Research Center for Precision Biomedicines, Changzhou, Jiangsu, China.
Chennan GeZonHon Biopharma Institute, Inc., Changzhou, Jiangsu, China; Jiangsu Engineering Research Center for Precision Biomedicines, Changzhou, Jiangsu, China.
Tao ZhangZonHon Biopharma Institute, Inc., Changzhou, Jiangsu, China; Jiangsu Engineering Research Center for Precision Biomedicines, Changzhou, Jiangsu, China.
Jun WangZonHon Biopharma Institute, Inc., Changzhou, Jiangsu, China; Jiangsu Engineering Research Center for Precision Biomedicines, Changzhou, Jiangsu, China.
He WangZonHon Biopharma Institute, Inc., Changzhou, Jiangsu, China; Jiangsu Engineering Research Center for Precision Biomedicines, Changzhou, Jiangsu, China.
Yu ZhuangZonHon Biopharma Institute, Inc., Changzhou, Jiangsu, China; Jiangsu Engineering Research Center for Precision Biomedicines, Changzhou, Jiangsu, China.
Zhen XuZonHon Biopharma Institute, Inc., Changzhou, Jiangsu, China; Jiangsu Engineering Research Center for Precision Biomedicines, Changzhou, Jiangsu, China.
Na DingZonHon Biopharma Institute, Inc., Changzhou, Jiangsu, China; Jiangsu Engineering Research Center for Precision Biomedicines, Changzhou, Jiangsu, China.
Bruce Yong MaZonHon Biopharma Institute, Inc., Changzhou, Jiangsu, China; Jiangsu Engineering Research Center for Precision Biomedicines, Changzhou, Jiangsu, China. Electronic address: bymzhsci@zonhonbio.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exogenous plasma kallikrein 1 (KLK1) supplementation is hypothesized to have both immediate and long-lasting actions that may improve outcomes following acute ischemic stroke. ZHB103, a polyethylene glycol (PEG)-modified long-acting recombinant human KLK1 (LA-rhKLK1), has been developed as a candidate for exogenous KLK1 supplementation in stroke patients and for the prevention of stroke. In pharmacokinetic and toxicokinetic studies, ZHB103 exhibited high bioavailability, a prolonged half-life (T

Indexed as

KallikreinsNeuroprotective AgentsStrokeTissue KallikreinsAnimalsHumansMacaca fascicularisMaleRatsRats, Sprague-DawleyRecombinant ProteinsKallikreinsNeuroprotective AgentsRecombinant ProteinsTissue KallikreinsIntramuscular administrationIschemic strokeLong-term effectPEGTissue kallikreinZHB103

Identifiers

PMID41547653
PMCPMC12976534

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.